San Diego, CA -- (SBWire) -- 05/05/2021 --Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Xeris Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Chicago, IL based Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.
On or around June 20, 2018, Xeris conducted its initial public offering ("IPO"), selling 5,700,000 shares of common stock priced at $15.00 per share.
On March 9, 2021, Xeris Pharmaceuticals, Inc announced its fourth quarter and full year 2020 results. Xeris Pharmaceuticals, Inc. reported that its annual Total Revneue rose from $2.72 million in 2019 to $20.15 million in 2020, and that its Net Loss declined from $125.58 million in 2019 to $91.13 million in 2020. However, Xeris Pharmaceuticals, Inc reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.
Shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) declined to $3.98 per share on March 9, 2021.
Those who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc.
An investigation on behalf of investors in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) shares over potential wrongdoing at Xeris Pharmaceuticals, Inc. was announced.